PCN76 HEALTH-RELATED QUALITY OF LIFE EVALUATION IN ROMANIAN CANCER PATIENTS  by Mihailov, MD et al.
PCN74
A SERVICE EVALUATIONTO COMPARE SECONDARY CARE
RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS
INTHETREATMENT OF METASTATIC COLORECTAL
CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE
(NHS) PERSPECTIVE
Millar DR1, Corrie P2, Hill M3, Pulfer A4
1Roche Products Ltd,Welwyn Garden City, UK, 2Addenbrooke’s
Hospital, Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK, 3Maidstone Hospital, Maidstone and Tunbridge Wells
NHS Trust, Maidstone, UK, 4pH Associates, Marlow, UK
OBJECTIVES: Capecitabine’s mCRC license was recently
extended supporting its use in combination therapy. XELOX
(oral capecitabine + intravenous (IV) oxaliplatin) in 21 day
cycles is non-inferior to FOLFOX-6 (IV 5-ﬂuorouracil, folinic
acid and oxaliplatin) in 14 day cycles (Ducreux et al, ASCO
2007). This evaluation was conducted to provide empirical evi-
dence of the relative NHS resource implications of using XELOX
and FOLFOX-6. METHODS: A prospective time-and-motion
study was conducted in two UK hospitals. Preparation, dispens-
ing and administration of infusions and insertion of a central
venous access device (CVAD) were observed by an independent
researcher. Staff and capital item utilisation were recorded.
Resource utilisation per course was derived from mean observed
activity durations multiplied by per protocol frequency over an
assumed typical treatment duration of 24 weeks. RESULTS:
Forty-six episodes of dispensing related activity were observed
along with 33 administration episodes, XELOX (n = 18) and
FOLFOX-6 (n = 15), and 7 of CVAD insertion. A mean of 98
minutes (SD = 15) staff time was required for CVAD insertion.
Mean staff time for preparation and dispensing of XELOX and
FOLFOX-6 was 24 minutes (SD = 11) vs. 31 minutes (SD = 4),
and for administration 39 minutes (SD = 15) vs. 68 minutes
(SD = 23). Per 24 week course, staff contact time for XELOX
was 39% and 43% that of FOLFOX-6 in centres 1 and 2
respectively, representing a difference of 11.5 hours and 12.2
hours. Additional chair time per patient course for FOLFOX-6
compared to XELOX was 14.5 hours and 23.2 hours for centres
1 and 2 respectively. CONCLUSIONS: XELOX requires less
pharmacy and administration time, and use of capital items, per
cycle than FOLFOX-6 and did not require the insertion of a
CVAD. This combined with a longer cycle length means that
XELOX is associated with considerable efﬁciency savings in
terms of NHS staff and patient time compared to FOLFOX-6.
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OBJECTIVES: In a phase III randomised trial in patients with
mRCC, sunitinib, an oral multitargeted receptor tyrosine kinase
inhibitor of VEGFRs, PDGFRs, KIT, FLT3 and RET, demon-
strated superior efﬁcacy versus interferon-alfa (IFN-a) in the
ﬁrst-line setting (P < 0.001) [Motzer et al., NEJM 2007]. We
present an updated analysis of the effects of geography and
treatment on patient-reported outcomes. METHODS: Patients
with mRCC received either oral sunitinib 50 mg/day in 6-week
cycles (4 weeks on treatment, 2 weeks off) or subcutaneous
IFN-a, 9 MU TIW. HRQoL outcomes were assessed using Func-
tional Assessment of Cancer Therapy–General (FACT-G),
FACT—Kidney Symptom Index (FKSI), FKSI disease-related
symptom subscale (FKSI-DRS), Euro-Qol health-utility index
(EQ-5D Index) and EQ visual analogue scale (EQ-VAS) question-
naires, administered on days 1 and 28 of each cycle. A longitu-
dinal mixed-effects model was used to analyse data for the EU
(France, Germany, Italy, Poland, Spain, UK) and US subsamples,
and the total (EU, US, Brazil, Russia, Australia, Canada) popu-
lation. RESULTS: At the time of analysis, patients (EU, n = 275;
US, n = 346; total, N = 750) had received up to 22 cycles of
treatment. All HRQoL endpoints favoured sunitinib over IFN-a
across all the groups. For most endpoints, between-treatment
differences were statistically signiﬁcant (P < 0.05). The treatment
differences within the US and EU subpopulations were similar
across all endpoints apart from one FKSI symptom. Sunitinib
provided a signiﬁcant beneﬁt over IFN-a for most of the nine
PRO endpoints (P < 0.05). Exceptions were EQ-5D in both the
EU (P = 0.74) and US (P = 0.25) subpopulations, and the physi-
cal and social wellbeing FACT-G scores in the EU group
(P = 0.23 and P = 0.12, respectively). CONCLUSIONS: In the
ﬁrst-line setting for mRCC therapy, all HRQoL endpoints
favoured sunitinib over IFN-a. This beneﬁt was generally main-
tained when compared across the US and EU subpopulations,
suggesting the generalisability of effects across geographic
regions.
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OBJECTIVES: wer to assess HRQOL and utilities in adult
cancer patients, using Romanian version of EQ-5D question-
naire, and to evaluate the inﬂuence of patients’ age, cancer
type, remission state and stem cell transplantation on HRQOL
and utilities METHODS: We analyzed 30 adult cancer patients
(6 with leukemia, 17 with lymphoma and 7 with solid tumors),
aged between 18–65 years, registered and treated in “Louis
Turcanu” Hospital Timisoara. Inclusion criteria were: onco-
logic disease, age > 18 years, IQ > 100 and voluntary participa-
tion on the study. Mean age of the patients was 29.9 years.
RESULTS: Patients younger than 30 years had statistically sig-
niﬁcant lower Qol scores in mobility domain (p = 0.0338), and
had less anxiety and depression (p = 0.0333). Cancer type had
statistically signiﬁcant inﬂuence only on mobility (p = 0.0071)
and self-care (p = 0.0400) domains and also on VAS utility
values (p = 0.0245). Remission had statistically signiﬁcant inﬂu-
ence on mobility and self-care domains (p < 0.0001), and no
inﬂuence on other domains and on utilities, although patients
in remission state had higher descriptive and VAS utility values.
Stem cell transplantation had improved mobility (p = 0.0009),
self-care (0.0487) and usual activities (0.0089) but didn’t inﬂu-
enced utilities. CONCLUSIONS: EQ-5D is a useful instrument
in assessing quality of life in cancer patients, allowing compari-
sons between different patient groups and providing important
data. This instrument appears to be a reasonably measure
which can be administered for self-completion in cancer
patients.
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